Dec 11 (Reuters) - Shares of Peter Thiel-backed AbCellera Biologics Inc, which is co-developing antibody therapies with Eli Lilly and Co for the treatment of COVID-19, surged in their debut on Friday, giving the company a market capitalization of $16.18 billion. AbCellera’s shares opened at $61 on the Nasdaq, 204% above their upwardly revised initial public offering (IPO) price of $20 apiece on Thursday. The Canadian firm had raised $483 million in its IPO.